{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:39:37Z","timestamp":1782484777104,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.esmorw.2024.100045","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:04:31Z","timestamp":1717416271000},"page":"100045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-7517","authenticated-orcid":false,"given":"H.","family":"Jourdain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Di Meglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Haddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmorw.2024.100045_bib1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.esmorw.2024.100045_bib2","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmorw.2024.100045_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmorw.2024.100045_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmorw.2024.100045_bib5","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev \u00c9pid\u00e9miol Sant\u00e9 Publique"},{"issue":"9","key":"10.1016\/j.esmorw.2024.100045_bib6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.7326\/M22-0988","article-title":"Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France","volume":"175","author":"Botton","year":"2022","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100045_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2021-000104","article-title":"Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study","volume":"1","author":"Bouillon","year":"2022","journal-title":"BMJ Med"},{"key":"10.1016\/j.esmorw.2024.100045_bib8","article-title":"Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study","volume":"372","author":"Weill","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.esmorw.2024.100045_bib9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/MLR.0000000000001745","article-title":"The economic burden of disease in France from the National Health Insurance Perspective: the healthcare expenditures and conditions mapping used to prepare the French social security funding act and the public health act","volume":"60","author":"Rachas","year":"2020","journal-title":"Med Care"},{"key":"10.1016\/j.esmorw.2024.100045_bib10","article-title":"Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people","volume":"8","author":"Semenzato","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100045_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-021-06469-0","article-title":"Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review","volume":"194","author":"Perez","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmorw.2024.100045_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231152847","article-title":"Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting","volume":"15","author":"Assi\u00e9","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2024.100045_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40263-019-00611-9","article-title":"Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case\u2013control study using automated health data sources","volume":"33","author":"Pladevall-Vila","year":"2019","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.esmorw.2024.100045_bib14","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/j.clbc.2019.10.001","article-title":"Predicting thrombocytopenia in patients with breast cancer treated with ado-trastuzumab emtansine","volume":"20","author":"Modi","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100045_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/bcp.14972","article-title":"Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients","volume":"88","author":"Scailteux","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.esmorw.2024.100045_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2215\/CJN.10230819","article-title":"Trends and outcomes with kidney failure from antineoplastic treatments and urinary tract cancer in France","volume":"15","author":"Mansouri","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.esmorw.2024.100045_bib17","series-title":"R: a language and environment for statistical computing","year":"2022"},{"key":"10.1016\/j.esmorw.2024.100045_bib18","unstructured":"Wickham H, Fran\u00e7ois R, Henry L, M\u00fcller K. dplyr: a grammar of data manipulation. 2022. https:\/\/dplyr.tidyverse.org\/. Accessed November 24, 2022."},{"key":"10.1016\/j.esmorw.2024.100045_bib19","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.esmorw.2024.100045_bib20","series-title":"A\u00a0package for survival analysis in R","author":"Therneau","year":"2022"},{"issue":"7","key":"10.1016\/j.esmorw.2024.100045_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2024.100045_bib22","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2024.100045_bib23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmorw.2024.100045_bib24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/cncr.28465","volume":"120","author":"Welslau","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmorw.2024.100045_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/cer-2020-0201","article-title":"Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer","volume":"10","author":"Ramagopalan","year":"2021","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.esmorw.2024.100045_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.breast.2022.03.004","article-title":"Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort","volume":"63","author":"Moinard-Butot","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.esmorw.2024.100045_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.breast.2023.01.007","article-title":"Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: a real-world study","volume":"69","author":"Sanglier","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.esmorw.2024.100045_bib28","article-title":"Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience","volume":"24","author":"Battisti","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100045_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2009.03.001","article-title":"A\u00a0most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies","volume":"63","author":"Bosco","year":"2010","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"17","key":"10.1016\/j.esmorw.2024.100045_bib30","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.esmorw.2024.100045_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10549-016-3845-5","article-title":"Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis","volume":"157","author":"Di Meglio","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmorw.2024.100045_bib32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100045_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jnci\/60.1.93","article-title":"Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication 2","volume":"60","author":"Eagan","year":"1978","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.esmorw.2024.100045_bib35","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/1097-0142(19800901)46:5<1104::AID-CNCR2820460505>3.0.CO;2-T","article-title":"A\u00a0phase i-ii study of maytansine utilizing a weekly schedule","volume":"46","author":"Franklin","year":"1980","journal-title":"Cancer"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T04:37:53Z","timestamp":1718599073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820124000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":34,"alternative-id":["S2949820124000237"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100045","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100045"}}